Table 1.

Patient, disease and treatment characteristics (n=303) – excluded non-adenocarcinoma (n=5)

Patient characteristics
Age, years
Median (range)	70 (33–90)
Gender
Male	152 (50.2%)
Female	151 (49.8%)
Race
Caucasian	277 (91.4%)
Other	12 (4.0%)
Unknown	14 (4.6%)
Body mass index
Median (range)	24.8 (14.5–45.8)
Comorbidities
Diabetes	176 (58.1%)
Coronary artery disease	37 (12.2%)
Hyperlipidemia	73 (24.1%)
Hypertension	207 (68.3%)
Medications
Metformin	41 (13.5%)
Pancreatic enzymes	130 (42.9%)
Sulfonylurea	23 (7.6%)
Insulin	158 (52.1%)
Statin (active use during treatment)	71 (23.4%)
Statin (before or at diagnosis)	59 (19.5%)
Glucocorticoid	91 (30.0%)
Beta-blocker (before or at diagnosis)	53 (17.5%)
Beta-blocker (active use)	107 (35.3%)
Disease characteristics
Histology
Adenocarcinoma	303 (100%)
Lymph node status
cN0	127 (41.9%)
cN+	164 (54.1%)
Not reported	12 (4.0%)
Resectability
Unresectable	149 (49.2%)
Borderline resectable	40 (13.2%)
Resectable	111 (36.6%)
Unknown	3 (1.0%)
Treatment characteristics
Surgery
Yes	136 (44.9%)
No	167 (55.1%)
Immunotherapy
Yes	12 (4.0%)
No	291 (96.0%)
Chemotherapy
Yes	248 (81.8%)
No	55 (18.2%)